Unfavorable side effects to first line anti-tuberculosis drugs
https://doi.org/10.21292/2075-1230-2016-94-5-42-45
Abstract
The article presents the study of frequency of unfavorable side effects to anti-tuberculosis drugs in new pulmonary tuberculosis patients in Regional Clinical TB Dispensary in Astrakhan in 2012-2013. The study reflects the type and nature of unfavorable side effects to specific drugs. It has been found out that side effect occur more often in case of combination of TB drugs compared to one TB drugs. The efficiency of specific therapy in case of side effects has been demonstrated.
About the Authors
N. A. Stepanova
Astrakhan State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant of Tuberculosis Control Department,
121, Bakinskaya St., Astrakhan, 414000
E. N. Streltsova
Astrakhan State Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head of Tuberculosis Control Department,
121, Bakinskaya St., Astrakhan, 414000
Kh. M. Galimzyanov
Astrakhan State Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Rector,
121, Bakinskaya St., Astrakhan, 414000
B. I. Kantemirova
Research Institute of Regional Infectious Pathology
Russian Federation
Doctor of Medical Sciences, Director of Research Institute of Regional Infectious Pathology
Russian Federation
Doctor of Medical Sciences, Director of Research Institute of Regional Infectious Pathology
References
1. Voznenko A.A. Lekarstvennoindutsirovannye porazheniya pecheni u bol’nykh tuberkulezom organov dykhaniya i puti ikh preodoleniya. Diss. kand. med. nauk. [Drug-induced liver lesions in respiratory tuberculosis patients and ways of their management. Cand. Diss.]. Moscow, 2012, 22 p.
2. Ivanova D.А., Borisov S.E., Ryzhov А.M. et al. Frequency, nature and risk factors of drug-induced liver lesions in the treatment of new tuberculosis patients. Tub., 2013, no. 11, pp. 25-31. (In Russ.)
3. Kantemirova B.I. Kliniko-farmakologicheskie podkhody k povysheniyu effektivnosti i bezopasnosti primeneniya lekarstvennykh sredstv v pediatricheskoy praktike Diss. dokt. med. nauk. [Clinical and pharmacological approaches to enhancement of efficiency and safety of drug use in the pediatric practice. Doct. Diss.]. Volgograd, 2013, 43 p.
4. Kantemirova B.I., Griganov V.I., Shilova А.А. et al. The issue of unfavorable side effects to medications. Astrakhan. Med. Journal, 2011, no. 4, pp. 8-12. (In Russ.)
5. Kontseptsiya khimioterapii i etiologicheskoy (mikrobiologicheskoy i molekulyarnobiologicheskoy) diagnostiki tuberkulyoza v Rossiyskoy Federatsii na sovremennom etape. [Concept for chemotherapy and etiological (microbiological and molecular-biological) diagnostics of tuberculosis in the Russian Federation on the current stage]. Moscow, Triada Publ., 2011. 53 p.
6. Livchane E. Lekarstvennaya neperenosimost, metody eye diagnostiki i korrektsii pri lechenii bolnykh tuberkulezom legkikh protivituberkuleznymi preparatami rezervnogo ryada. Diss. kand. med. nauk. [Drug intolerance, methods of its diagnostics and management during treatment of pulmonary tuberculosis patients with second line drugs. Cand. Diss.]. Moscow, 2003, 20 p.
7. Mishin V.Yu., Chukanov V.I., Grigoriev Yu.G. Pobochnye deystviya protivotuberkuleznykh preparatov pri standartnykh i individualizirovannykh rezhimakh khimioterapii. [Adverse reactions of anti-tuberculosis drugs by the standard and individual chemotherapy regimens]. Moscow, Kompyuterburg Publ., 2004, 208 p. (In Russ.)
8. Mordyk А.V., Bereznikov А.V., Konev V.P. Drug-induced liver lesions with persistent course and poor response to treatment: results of internal expertise and clinical follow-up. Probl. Tub., 2010, no. 4, pp. 43-47. (In Russ.)
9. Mordyk А.V., Ivanova O.G., Nagibina L.А. et al. Medications based on succinic acid in the integral treatment of tuberculosis patients. Probl. Tub., 2014, no. 6, pp. 61-64. (In Russ.)
10. Edict no. 109 by RF MoH as of 21.03.2003 On Improvement of TB Control Measures in the Russian Federation. Moscow, 2003, 347 p. (In Russ.)
11. Sukhanov D.S., Vinogradova T.I., Zabolotnykh N.V. et al. Comparative study of hepatoprotective action of remaxol, reamberin and adamethioninum in liver lesion induced by anti-tuberculosis drugs (experimental research). Antibiot. i Khimioterap., 2011, vol. 56, no. 12, pp. 12-16. (In Russ.)
12. Khomenko A.G. Tuberkulez. Rukovodstvo dlya vrachey. [Tuberculosis.Doctors’ Manual]. Edited by A.G. Khomenko, Moscow, Meditsina Publ., 1996, 496 p.
13. Yakovlev A.Yu. Reamberin v praktike infuzionnoy terapii kriticheskikh sostoyaniy. Prakticheskie rekomendatsii. [Reamberin in the infusion therapy of critical states. Guidelines]. St. Petersburg, 2011, 32 p.
14. Aziz H., Shubair M., Debari V.A. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. Curr. Med. Res. Opin., 2006, vol. 22, no. 1, pp. 217-221.
15. Babalik A., Arda H., Bakirci N. et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk. Toraks., 2012, vol. 60, no. 2, pp. 136-144.
16. Coca N.S., Oliveira M.S., Voieta I. et al. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity. Rev. Soc. Bras. Med., Trop. 2010, vol. 43, no. 6, pp. 624-648.
17. Donald P.R., van Helden P.D. Anti-tuberculosis chemotherapy: Progress in Respiratory Research / Basel:Karger, 2011.
18. Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J.Clin.Clin. and Experimental Hepatology, 2012, vol. 3, no. 1, pp. 37-49.
19. Shang P. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drugs induced liver injury (ATLI) in China/ P. Shang, Y. Xia, F. Liu. PLoS One, 2011, vol. 6, no. 7, pp. e21836.
20. WHO, Global tuberculosis report 2012. Geneva, World Health Organization, 2012 http://www.who.int/tb/publications/global_report/en/index.htm/ (accessed Dec 27, 2012).
Review
For citations:
Stepanova N.A., Streltsova E.N., Galimzyanov Kh.M., Kantemirova B.I. Unfavorable side effects to first line anti-tuberculosis drugs. Tuberculosis and Lung Diseases. 2016;94(5):42-45. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-5-42-45
Views:
5197
Email this article 